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Cost-Effectiveness
Psoriasis is a skin disorder that is characterized by scalyplaques, itching, and red-
ness.1 Of the nearly 8 million Ameri-
cans who have psoriasis, an estimat-
ed 30% have symptoms severe
enough to require treatment with
phototherapy (UV-B or psoralen
with UV-A [PUV-A]), oral systemic
medications (acitretin, cyclosporine,
and methotrexate), and/or biologic
agents (alefacept, efalizumab, eta-
nercept, and infliximab).1,2
Since 2003, the number of FDA-
approved biologic treatments of pso-
riasis has increased 3-fold. Currently,
there are more than a dozen biologic
agents for the management of psori-
asis either under FDA review or in
development.3,4 As demand for these
newer and more costly drugs meets
up with limited health systems re-
sources, MCOs and other health care
decision makers will need to better
evaluate the effectiveness and costs
of all therapies for moderate to se-
vere psoriasis.
The Psoriasis Area and Severity
Index (PASI) is the most frequently
cited measure of treatment effective-
ness for moderate to severe psoriasis
and is accepted by the FDA as a pri-
mary end point in clinical trials.5,6
Outcomes are often reported in
terms of average percentage change
in PASI score from baseline to end
point (PASI%). Clinically meaningful
outcomes are frequently reported as
achievement of at least 50% or 75%
improvement from baseline (PASI50
or PASI75).6,7
We sought to compare the cost-
effectiveness of phototherapy, oral
systemic medications, and biologic
outpatient treatments of moderate 
to severe psoriasis. In the absence of
head-to-head comparative trials, the
PASI—a clinically meaningful met-
ric—was used to measure treatment
effectiveness. The primary study
question was: From the perspective
of the US health care system (ie,
physicians, pharmacy and therapeu-
tics committee members, medical 
directors, clinical pharmacists, and
other health care professionals),
what are the comparative annual
costs to achieve PASI improvements
of 1%, 50%, and 75% using these se-
lected therapies for psoriasis? 
Methods
A systematic review of the literature
was conducted to identify studies 
reporting PASI% improvement for
UV-B, PUV-A, acitretin, cyclospor-
ine, methotrexate, alefacept, efali-
zumab, etanercept, and infliximab.
Also identified were studies examin-
ing PASI% improvement for com-
bined regimens of acitretin with
PUV-A or UV-B. These treatments
may have synergistic effects when
combined, thereby reducing the
overall number, duration, and cu-
mulative doses required to achieve
symptom improvement.8
The total annualized costs for
each treatment were calculated, as
was an annualized cost-effectiveness
ratio—the total annualized cost of
treatment divided by PASI% im-
A Cost Comparison of Treatments of 
Moderate to Severe Psoriasis
Cheryl S. Hankin, PhD, Steven R. Feldman, MD, PhD, Andy Szczotka, PharmD, Randolph C. Stinger, MD, 
Leslie Fish, PharmD, David L. Hankin, MBA
This study of the efficacy and cost-effectiveness of moderate to severe psoriasis
treatments compared phototherapy, oral systemic agents, and biologics from a
managed health care systems perspective. A literature review was conducted to
identify published studies reporting Psoriasis Area and Severity Index (PASI)
percentage improvement from baseline (PASI%) for selected treatments. The 
researchers then calculated total annualized costs. For each treatment, annualized
cost-effectiveness was calculated by dividing total annualized costs of treatment by
PASI%. The costs necessary to achieve clinically meaningful outcomes (PASI50
and PASI75) were then calculated. Of 3886 articles examined, 16 studies met 
inclusion criteria. Oral systemic medications, UV therapy, and UV therapy 
combined with acitretin appear to be the most cost-effective therapies for moderate
to severe psoriasis. (Drug Benefit Trends. 2005;17:200-214)
Key words: Cost-effectiveness • Psoriasis • Psoriasis Area and Severity
Index
Dr Hankin is president and chief scientific officer and Mr Hankin is chief operating of-
ficer at BioMedEcon LLC, San Jose, Calif. Dr Feldman is a board-certified dermatologist
and professor of dermatology, pathology, and public health sciences at Wake Forest Uni-
versity School of Medicine, Winston-Salem, NC. Dr Szczotka was senior vice president
of clinical services at MedImpact Healthcare Systems, Inc, San Diego, at the time he con-
tributed to this research. Dr Stinger is regional medical director at Humana, Cincinnati.
Dr Fish is director of pharmacy at Fallon Community Health Plan, Worcester, Mass.
0505DBT200028han.lay  4/29/05  4:36 PM  Page 200
May 2005   DRUG BENEFIT TRENDS 201
provement. The annualized cost-
effectiveness ratio provides the cost
to achieve a PASI score improvement
of 1% (PASI1). To obtain more clini-
cally meaningful outcomes, we 
multiplied the costs for PASI1 by 50
and 75 to estimate the costs to
achieve PASI50 and PASI75 for each
selected treatment.
Systematic review. AMEDLINE
search from 1966 to August 2004 was
performed for studies reported in
English with the terms “psoriasis”
and each of the following: acitretin,
cyclosporine (including the spellings
of ciclosporin and ciclosporine),
methotrexate, alefacept, efalizumab,
etanercept, infliximab, PUV-A, UV-
B, UV-B and acitretin, and PUV-A
and acitretin. Additional studies
were obtained after being identified
from citations in review articles.
One of the study authors as-
sessed each citation for relevance. Of
3885 articles identified from MED-
LINE and citation reviews, 84 were
deemed preliminarily to meet inclu-
sion criteria (described below) and
were retrieved. For each retrieved ar-
ticle, the same study author noted
the citation; study design; treat-
ment type(s), duration, and dose(s);
participant inclusion/exclusion cri-
teria; sample size; analytic approach;
study end points; results; and 
conclusions. 
Extracted summaries prepared
by the first author were evaluated for
final selection by the other study au-
thors. Consensus was achieved by
reference to original articles, discus-
sions during a day-long working-
group session, and subsequent com-
munications via telephone and e-
mail. Reviewers were not blinded to
articles’ authors, institutions, or pub-
lication journal because such meth-
ods do not appear to affect systemat-
ic review outcomes.9
Study inclusion and exclusion
criteria were designed to ensure that
the systematic review was conduct-
ed to minimize the introduction of
bias.10 Consistent with formulary re-
view processes typically conducted
by US health care systems, we in-
cluded only peer-reviewed, pub-
lished studies. Priority was given to
randomized, double-blind, placebo-
controlled trials.
Only studies that reported mean
PASI improvement from baseline
and that specified time to the end-
point assessment were included.
Other inclusion requirements were
that the sample size of participants
receiving active treatment was 10 or
more, participants were adults (age
18 years or older) with a diagnosis of
moderate to severe psoriasis or a
baseline PASI score of at least 8 (sig-
nifying at least moderate severity),
plaque psoriasis was the predomi-
nant subtype represented, and par-
ticipant recruitment was not based
on prior response to the targeted
treatment. In addition, only studies
were used that had a treatment du-
ration of between 6 and 14 weeks, 
specified the mean dose of treatment
(drug or number of phototherapy 
exposures), excluded as treatment
ancillary concomitant systemic ther-
apies or phototherapies, initiated
treatment as de novo rather than as
maintenance following stabilization,
and adminstered medication in dose
ranges within current product rec-
ommendations.
Excluded studies were those in
which the targeted treatment was
omitted and in which participants
were not randomized to treatment
conditions (for comparative trials).
Studies that were duplicates of ones
that we had already reviewed, that
did not apply an intent-to-treat
analysis, that did not include
dropouts in the analysis, and that
did not clarify the disposition of
dropouts were eliminated.11 Clinical
case studies or retrospective case re-
views, review articles, news articles,
and letters were excluded as well.
Calculation of costs. Total annu-
alized costs were calculated as the
sum of costs for medication or pho-
totherapy, treatment administration,
monitoring for potential treatment-
related adverse events, and treat-
ment of adverse events. Average
wholesale price (AWP) at January
2004 rates were used to calculate
costs for oral systemic medications
and biologic drugs.12 Costs for pho-
totherapy were calculated at 2004
Medicare reimbursement rates, us-
ing Evaluation and Management
(E&M) codes 96910 for UV-B and
96912 for PUV-A.13 For cyclospor-
ine,14 efalizumab15, and infliximab16
(the medications for which dosing is
based on patient body weight), we
assumed a weight of 75 kg (167 lb).
The following assumptions
were made regarding annualized
dosing regimens:
• For all oral systemics and efali-
zumab, therapy regimens reported
in the targeted studies remained
constant throughout the year.15
• For alefacept, based on product 
labeling, two 12-week courses of
treatment were administered.17
• For etanercept, following an initial
dose of 50 mg twice weekly, the
dose was reduced to 25 mg twice
weekly for the remainder of the
year.18
• For infliximab, initial dosing oc-
curred at 0, 2, and 6 weeks, fol-
lowed by administration every 8
weeks thereafter (9 total annual
administrations).16
• With regard to PUV-A, following
the active treatment regimen spec-
ified by the study protocol, pa-
tients received 1 PUV-A treatment
every week throughout the re-
mainder of the year.19
• With regard to UV-B, patients re-
ceived 2 UV-B treatments each
week for the remaining year.8,20
• For PUV-A or UV-B therapy with
acitretin, following the active treat-
ment regimen specified by the
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study protocol, patients received
acitretin 25 mg every other day
and UV-B or PUV-A once every
other week (the equivalent of once
weekly during autumn and winter
months and no treatment during
spring and summer).21
• For biologics that can be patient-in-
jected, such as etanercept and efa-
lizumab, there were no additional
treatment administration costs.
• For biologics that require intra-
venous (IV) injection (alefacept),
we applied the E&M code 90782
(subcutaneous injection) at 2004
Medicare reimbursement rates.22
• For biologics that require IV infu-
sion over 2 hours (infliximab), we
applied E&M codes 90780 (first
hour IV infusion) and 90781 (sec-
ond hour infusion).22
Because phototherapy, oral sys-
temic medications, and biologic
treatments are associated with the
potential for adverse events, contin-
ued patient monitoring is required.
Recommended monitoring regi-
mens are specified in product label-
ing for oral systemic medications
and biologic agents and in consensus
statements for phototherapies. These
recommendations were used to cal-
culate annual costs of monitoring at
2004 Medicare reimbursement rates. 
In addition, the literature was re-
viewed to identify risk factors for se-
Table 1. Summary of Symptom Improvement by PASI%
Treatment Study Specified Dose of Active Treatment Sample Size PASI%
Broadband UV-B Ramsay41 3/wk for 12 wk 164 80.1
Woo42 3/wk for 7 wk 50 83.7
Walters43 3/wk for 6 wk 11 47.0
Narrowband UV-B Walters43 3/wk for 6 wk 11 73.0
PUV-A Caca-Biljanovska55 4/wk for 6 wk, then 2/wk for 2 wk 40 92.9
Torras56 3/wk for 10 wk 113 61.1
Acitretin Gollnick57 48.2 mg/d 145 60.4
Cyclosporine Ellis58 3 mg/kg/d 85 52.0
Reitamo59 1.5 mg/kg/d 149 33.4
Methotrexate Chladek60 7.5 mg/wk 24 58.4
15 mg/wk 24 71.6
Alefacept Lebwohl23 15 mg/wk 507 45.0
Efalizumab Gordon24 1 mg/kg/wk 556 52.0
Lebwohl61 1 mg/kg/wk 597 51.0
Etanercept Leonardi62 50 mg 2/wk 652 64.2
Infliximab Chaudhari63 5 mg/kg at weeks 0, 2, and 6 33 82.8
UV-B* + acitretin Carlin64 UV-B 5 - 7/wk + acitretin 17 80.7
25 mg/d for 12 wk
PUV-A† + acitretin Lauharanta65 Acitretin 40 mg/d for 2 wk, 34 97.3
then acitretin 20 mg/d + 
PUV-A 3/wk for 8 wk
PASI%, average percentage change in Psoriasis Area and Severity Index score from baseline to end point; PUV-A, psoralen with UV-A.
*UV-B obtained from commercial tanning beds.
†Administered by bath.
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Table 2. Annualized Costs of Medication/UV Treatment
Treatment Regimen Annual Cost of Therapy
Therapy Specified Active Assumed Maintenance Medication (AWP)12 UV13,22 Total
Broadband UV-B* 3/wk for 12 wk41 2/wk for 40 wk — $4807 $4807
3/wk for 7 wk42 2/wk for 45 wk — $4600 $4600
3/wk for 6 wk43 2/wk for 46 wk — $4558 $4558
Narrowband UV-B* 3/wk for 6 wk43 2/wk for 46 wk — $4558 $4558
PUV-A† 4/wk for 6 wk, then 1/wk for 44 wk — $3737 $3737
2/wk for 2 wk55
3/wk for 10 wk56 1/wk for 42 wk — $3737 $3737
Acitretin 48.2 mg/d57 Constant daily dose $12,359 — $12,359
(two 25-mg tablets)
Cyclosporine 3 mg/kg/d58 Constant daily dose $5019 — $5019
(two 100-mg and one 
25-mg tablets)
1.5 mg/kg/d59 Constant daily dose $2789 — $2789
(one 100-mg and 
one 25-mg tablets)
Methotrexate 7.5 mg/wk60 Constant dose $595 — $595
(single tablet)
15 mg/wk60 Constant dose $1190 — $1190
(single tablet)
Alefacept 15 mg/wk23 Two 12-week $23,880 — $23,880
courses (single dose)
Efalizumab 1 mg/kg/wk24 Constant dose $17,836 — $17,836
(75 mg/wk, requiring 
1 vial with 50 mg of waste)
Etanercept 50 mg 2/wk 25 mg 2/wk for 40 wk $21,052 — $21,052
for 12 wk62 (1 vial contains 25 mg)
Infliximab 5 mg/kg at 375 mg every 8 wk for $24,898 — $24,898
wk 0, 2, and 663 46 wk (6 administrations), 
requiring 4 vials with 
25 mg of waste
UV-B‡ + acitretin UV-B: 5 - 7/wk UV-B 0.5/wk,§ acitretin $3792 — $3792
for 12 wk; acitretin: reduced to 25 mg (single
25 mg/d for 12 wk64 tablet) every other day
for 40 wk
PUV-A + acitretin Acitretin: 40 mg/d PUV-A 0.5/wk§ + $4437 $2336† $6773
(one 25-mg, one acitretin reduced to 
10-mg, and half 25 mg every other 
10-mg tablets) for day for 42 wk
2 wk, then 20 mg/d 
plus PUV-A 3/wk for 
8 wk65
PUV-A, psoralen with UV-A.
*Current Procedural Terminology (CPT) code 96910 ($41.44).
†CPT code 96912 ($51.90).
‡Because UV-B was obtained from commercial tanning beds, there was no cost to the health care system.
§Signifies every other week dosing.
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rious adverse events associated with
each treatment. These costs were cal-
culated as the product of each treat-
ment’s adverse event risk multiplied
by the cost of care associated with
the adverse event. The total costs of
treatment and method for determin-
ing cost-effectiveness were calculat-
ed by dividing the total costs of
care—drug or phototherapy costs,
administrative costs, monitoring
costs, and costs of adverse events—
by clinical outcomes, or the average
PASI% improvement.
Results
Among the 3886 articles identi-
fied from MEDLINE and citation 
reviews, we identified 16 articles, for
which there were 18 outcomes, to 
include in our calculation of PASI
improvement. A list of the citations,
treatments, and PASI% improve-
ment is presented in Table 1.
Cost analysis. Table 2 presents
the costs associated with each treat-
ment and assumptions regarding
maintenance therapy. For efalizu-
mab, there were nearly identical
PASI findings of 51%23 and 52%24;
thus, the slightly higher findings
were used to represent the efficacy
for this drug. Table 3 presents moni-
toring regimens and associated costs
for the targeted treatments, and
Table 4 details costs associated 
with the administration of biologic
agents.
Because each treatment may be
associated with risk of serious ad-
verse events, the literature was re-
viewed to provide guidance regard-
ing 1-year risk-adjusted costs for 
adverse events for each treatment at
dosages specified in Table 2.
Adverse events associated with
broadband UV-B. Pasker-de Jong and
associates25 found that the risk of
UV-B–associated nonmelanoma skin
cancer (NMSC) is unlikely to exceed
2% per year. In 1995, annual costs for
NMSC treatment among Medicare
patients were estimated at $702.26 In
2004 dollars ($875), the risk-adjusted
cost of broadband UV-B–related
NMSC was $18 ($875  2%).
Adverse events associated with nar-
rowband UV-B. Given its limited
availability, little is known about the
safety of narrowband UV-B. Thus,
we assumed equivalent risk and
costs for broadband UV-B–related
NMSC ($18, described above).
Adverse events associated with
PUV-A. Compared with the general
population, patients with exposure
to high-dose PUV-A have a substan-
tially increased risk of developing
squamous cell carcinoma (SCC); this
risk is approximately 4-fold at 5
years.19 The risk of SCC among the
general population is 0.3%.27 There-
fore, we assumed an SCC incidence
of 1.2% (4-fold risk) occurring 5 years
after initial PUV-A exposure. At an
annual cost of $875 for NMSC treat-
ment, the annual per-patient risk-ad-
justed cost of PUV-A–related NMSC
was $11 ($875  1.2%). (We did not
recalculate this 5-year estimate to a
2004 value because its contribution
to total costs is negligible.)
Adverse events associated with aci-
tretin. The most common acitretin-
related adverse event is hyperlipid-
emia, which may occur in up to 33%
of persons taking the drug.28-30 Use 
of antilipid agents, weight loss, or
changes in diet may improve lipid
levels.30 We assumed that hyperlip-
idemia would develop in 33% of pa-
tients receiving acitretin. We know of
no studies describing the percentage
of patients taking acitretin who have
hyperlipidemia and who receive an-
tilipid treatment; we conservatively
assumed that 25% of such patients
would require antilipid agents. This
represents 8.25% (33%  25%) of all
patients receiving acitretin. We fur-
ther assumed a daily cost of $2.76 
for antilipids (20 mg atorvastatin at
AWP).12 Thus, the annual per-patient
risk-adjusted cost of acitretin-related
hyperlipidemia is $80 ($2.76  8.25%
 365 days).
Adverse events associated with cy-
closporine. The most common cy-
closporine-related adverse event at
doses of less than 5 mg/kg/d is hy-
pertension, which occurs among
8.5% to 27% of persons treated.31 Per-
sons who have cyclosporine-in-
duced hypertension best respond to
calcium channel antagonists for low-
ering blood pressure levels.31 We se-
lected a midpoint of 17.75% as the
cyclosporine-related hypertension
risk. At a daily cost of $2.10 for calci-
um channel antagonists (300 mg
long-acting diltiazem at AWP),12 the
annual per-patient risk-adjusted cost
of cyclosporine-related hypertension
is $136 ($2.10  17.75%  365 days).
Adverse events associated with
methotrexate. Bone marrow suppres-
sion and lymphoma, the most wor-
risome methotrexate-related adverse
effects, are rare among psoriasis pa-
tients.29 Whereas hematologic toxici-
ty risk varies from 3% to 9%, sup-
plementation with folic acid, 1 to 
5 mg/d, dramatically reduces this
risk.29 The most consistent evidence
of methotrexate-related side effects
pertains to hepatic function.32-35
However, we are not aware of any
research regarding risk after only 1
year of methotrexate use at dosages
of less than 20 mg/wk. Therefore,
we assume no risk-adjusted costs for
methotrexate-related adverse events.
Adverse events associated with
combined phototherapy and acitretin.
Acitretin dosages are commonly re-
duced by half when administered in
combination with phototherapy.36
Therefore, we halved our previous
33% estimate for acitretin-related hy-
perlipidemia to 16.5% when acitretin
was administered in combination
with phototherapy. Of those patients
receiving combined treatment, we
further assumed that 25% would re-
quire lipid level–lowering agents.
Thus, 4.13% (16.5%  25%) of pa-
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tients who received phototherapy
and acitretin in combination would
require an antilipid medication. At a
cost of $2.76 per day for antilipids (20
mg atorvastatin at AWP), the annual
per-patient risk-adjusted cost of hy-
perlipidemia related to combination
therapy was $42 ($2.76  4.13% 
365 days).
Acitretin has been documented
to have tumor-suppressive charac-
teristics37,38; acitretin used in com-
bination with PUV-A is associated
with a 30% reduction in risk of
NMSC developing, compared with
use of PUV-A alone.39 Consequently,
we assumed an incidence of NMSC
occurring 4 years after exposure to
PUV-A and acitretin of 0.8% (70% of
the 1.2% risk associated with PUV-A
monotherapy), with an annual per-
patient risk-adjusted cost of $7 ($875
 0.8%). For combined UV-B and 
acitretin therapy, the annual per-
patient risk-adjusted cost of NMSC
was $12 ($875  [2%  70%]). Thus,
the risk-adjusted costs of adverse
events were estimated to be $54 for
combined UV-B and acitretin and
$49 for PUV-A plus acitretin.
Adverse events associated with bio-
logics. Experts caution that given the
immunosuppressive action of some
biologics, there is the possibility of
increased risk of long-term carcino-
genicity.40 Because biologics have not
Table 3. Monitoring Regimens per Product Labeling (Medications) or 
Consensus Statements (Phototherapies)
Therapy Monitoring Regimen for 1 Year of Treatment Total Annual Cost*
Broadband UV-B18 Complete physical, 1 $106
Narrowband UV-B18 Complete physical, 1 $106
Psoralen with UV-A19 Complete physical, 1 $106
Acitretin28 Complete physical, 1; Liver function, 15; $618
Lipid panel, 15
Cyclosporine14 Complete physical, 1; Brief examination, 16; $1794
Liver function, 13; Lipid panel, 16; 
Serum creatinine, 17; Electrolytes, 16; 
Magnesium, 16; Blood urea nitrogen, 16; 
Uric acid, 13; CBC count, 16
Methotrexate66 Complete physical, 1; Liver function, 13; $1188
CBC count, 13; Renal function, 13;
Chest x-ray, 1; Liver biopsy, 0.5 
(recommended every other year)
Alefacept17 Complete physical, 1; CD4 T-lymphocyte, 26 $2412
Efalizumab15 Complete physical, 1; Red blood cell count, $163
automated, 7
Etanercept21 Complete physical, 1 $106
Infliximab16 Complete physical, 1; Tuberculosis skin test, 1 $116
UV-B + acetretin20,36 Complete physical, 1; Liver function, 15; $618
Lipid panel, 15
Psoralen with  Complete physical, 1; Liver function, 15; $618
UV-A + acitretin20,36 Lipid panel, 15
*Costs were based on 2004 Medicare rates13 and were calculated as follows: Complete physical, $105.66; Brief examination, $8.96; Liver function,
$15.43; Lipid panel, $18.72; Serum creatinine, $10; CD4 T-lymphocyte, $88.71; Electrolytes, $13.24; Magnesium, $12.65; Blood urea nitrogen, $7.45; 
Uric acid, $8.53; Complete blood cell (CBC) count, $14.68; Red blood cell count, automated, $8.12; Tuberculosis skin test, $10; Renal function, $16.39;
Chest x-ray, $35.84; Liver biopsy, $884 (includes $200 reimbursement for biopsy procedure and assumed additional facility costs for ambulatory services
of $684).
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been available long enough to de-
termine whether they contribute to
development of malignancies, we
did not incorporate biologic-related
adverse events into our assumptions
of risk-adjusted adverse event costs.
Table 5 summarizes our assump-
tions of risk-adjusted costs of ad-
verse events by treatment. Table 6
presents annualized costs of treat-
ment, PASI% efficacy, and costs 
to achieve PASI1, PASI50, and
PASI75.
Discussion
Oral systemic medications, UV ther-
apy, and UV therapy in combination
with acitretin appear to be the most
cost-effective treatments of moderate
to severe psoriasis. The cost to
achieve PASI1 ranged from $31
(methotrexate) to $602 (alefacept),
and annualized costs to achieve
PASI75, a clinically meaningful
threshold of efficacy, ranged from
approximately $2300 to $45,000. Key
drivers of cost-effectiveness were
medication or phototherapy costs
and PASI efficacy rates. Treatment
administration, monitoring, and
risk-adjusted costs for adverse
events contributed little to total costs
of care.
Cost is an important factor in
both formulary determination and
clinical decision making. Other fac-
tors include the safety of treatments.
The most cost-effective treatment
was methotrexate, which has serious
potential long-term risks not calcu-
lated in our analysis. These risks will
need to be weighed when compar-
ing use of methotrexate with other
options.
Phototherapy, as monotherapy
and in combination with acitretin,
appears to hold an intermediate po-
sition in terms of cost-effectiveness
and has an excellent short- and long-
term safety profile. Health care sys-
tems should reconsider any current
disincentives in plan design for ac-
cess to these treatments.
Wide variation in PASI score im-
provement (47% to 80.1%) and asso-
ciated cost-effectiveness ($56 to $100)
was found for broadband UV-B. We
included 2 randomized, placebo-
controlled trials that reported PASI
improvement of approximately
80%.41,42 A small (n = 11), open-label
study reported PASI improvement
of 47%.43 Although this study meets
all inclusion criteria, results may not
be as robust as those of the larger,
double-blind, placebo-controlled tri-
als. Consequently, the cost-effective-
ness of broadband UV-B may be 
underestimated when this smaller
study’s PASI improvement of 47% is
applied.
Our estimate of combination
broadband UV-B and acitretin ther-
apy is based on efficacy of treatment
from commercial tanning beds;
therefore, no health care systems–re-
lated costs for UV-B were included. 
If UV-B were administered in a clin-
ic (5 exposures per week and 25 mg
acitretin for 12 weeks, followed by
twice weekly exposures and 25 mg
acitretin every other day for the re-
mainder of the year), total annual
costs are estimated to be $7108; at 
a PASI% efficacy of 80.7%, costs to
achieve PASI1, PASI50, and PASI75
would be $88, $4400, and $6600, 
respectively.
Study Limitations
Our study has several limitations.
First, only peer-reviewed, published
studies were included. As a result of
potential publication bias, treatment
effects (ie, PASI outcomes) may 
be overestimated.44 As previously
noted, our approach is consistent
with the formulary review process
typically conducted by US health
care systems. Second, we excluded
studies in languages other than En-
glish. However, our review of hand-
searched bibliographies does not
suggest that this restriction caused
any important studies to be missed.
Third, we evaluated treatment
effectiveness solely in terms of PASI.
Other indices, such as global assess-
ments of improvement, willingness-
to-pay, quality of life, and duration
of remission, may be used in clinic
settings or be more sensitive to pa-
tient preferences, response to thera-
py, level of suffering, or treatment ef-
Table 4. Biologics Administration Costs
No. of Clinician 2004 Medicare 
Drug Mode of Delivery Administrations/y Reimbursement Rate13 Total Annual Costs
Alefacept IM bolus 24 $33.60 $806
Efalizumab SC 0 (patient-administered) — $0
Etanercept SC 0 (patient-administered) — $0
Infliximab 2-h IV infusion 9 $157.99 $1422
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fects.45-49 However, the PASI was se-
lected because of its acceptance by
the FDA as an index of treatment ef-
ficacy, its use in clinical trials across
targeted treatments, and its corre-
spondence to clinically meaningful
outcomes.
Physicians widely vary in their
clinical and billing practices; there-
fore, the monitoring regimen includ-
ed in our cost calculations reflects
product labeling recommendations
rather than actual practice. Further-
more, we included a conservative es-
timate of charges for administration
of biologics and phototherapy. To 
the extent that actual practice varies
from our assumptions, costs of treat-
ment should be adjusted according-
ly. To facilitate such adjustment, we
have made our cost assumptions as
transparent as possible.
Another limitation was that this
analysis was developed for patients
with moderate to severe “skin” pso-
riasis. Consequently, findings may
not extend to patients with psoriatic
arthritis. In addition, this study was
limited by the short-term nature of
extant study results (1 year) and,
thus, we did not feel confident in ex-
tending reported efficacy and safety
findings beyond this 1-year period.
Because psoriasis is a lifelong dis-
ease, many patients go in and out of
treatment; a Markov analysis might
be more appropriate to study such
treatment, but we know of no stud-
ies that examined actual utilization
across a range of psoriasis treat-
ments. Therefore, we calculated the
comparative cost-effectiveness re-
quired to achieve 1 year of success-
ful treatment. Furthermore, our dos-
ing assumptions ignore potential
Table 5. Adverse Event Risk Costs and Annual Risk-Adjusted Costs by Treatment
Annualized Risk-Adjusted 
Therapy Risk of Adverse Event Costs of Adverse Events Costs of Adverse Events
UV-B NMSC: 2% annual incidence25 $875*/y26 $18
PUV-A NMSC: 5-year risk, 1.2%19,27 $875*/y26 $11
Acitretin Hyperlipidemia: 8.25% of 20 mg atorvastatin: $83
patients will require lipid- $2.76/d (AWP)12
lowering agents28,61,62
Cyclosporine Hypertension: 18% of patients 300 mg long-acting diltiazem: $138
will require calcium channel $2.10/d (AWP)12
antagonists31
Methotrexate Unknown at dosages — —
< 20 mg/wk
Alefacept Unknown — —
Efalizumab Unknown — —
Etanercept Unknown — —
Infliximab Unknown — —
UV-B + acitretin Hyperlipidemia: 4.13% of 20 mg atorvastatin: $54
patients will require lipid- $2.76/d (AWP)12 + $875*/y26
lowering agents28,61,62
NMSC: 5-year risk, 1%25
(acitretin reduced risk 70%39)
PUV-A + acitretin Hyperlipidemia: 4.13% of 20 mg atorvastatin: $49
patients will require lipid- $2.76/d (AWP)12 + $875*/y26
lowering agents28,61,62
NMSC: 5-year risk, 2%19,27
(acitretin reduced risk 70%39)
NMSC, nonmelanoma skin cancer; PUV-A, psoralen with UV-A.
*Adjusted to 2004 dollars.
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“dosage creep,” which would have
increased cost estimates and de-
creased cost-effectiveness results.
The systematic review selection
criteria used in this analysis may
have been too stringent—we were
surprised to find so few studies
meeting our criteria for inclusion. 
In a review of the quality of psoria-
sis-related studies published from 
1977 through 2000, consistently poor
quality in study design and report-
ing of results was found.50 Given that
such a small number of studies met
our criteria for inclusion, we had
very few data points to consider.
Consequently, our findings are limit-
ed to the data available.
Despite its limitations, our study
had several strengths. First, we con-
ducted a systematic, evidence-based
approach to the identification of ef-
fectiveness across treatments and ap-
plied these results to our cost-effec-
tiveness calculations. Second, we in-
cluded risk-adjusted costs of adverse
events in calculations of total costs.
Third, we considered the clinical rel-
evance of our findings in terms of
PASI50 and PASI75.
Conclusion
Few systematic reviews of the effec-
tiveness of treatments of psoriasis
have been conducted. None of them
were completed before biologics en-
tered the market, and all of them in-
cluded studies in which doses ad-
ministered exceeded current recom-
mendations.48,51,52 There have also
been few studies of psoriasis that
compared the cost-effectiveness of
phototherapies, oral systemic med-
ications, and biologics. Rapp and as-
sociates53 estimated the cost of psori-
asis treatment in terms of PASI75.
Table 6. Annualized Costs of Care, Efficacy, and Cost-Effectiveness
Annualized Costs of Care, $
Cost-Effectiveness, $
Cost/y, Cost/y, 
Treatment Rx Del Mon AE Total PASI% PASI1 PASI50 PASI75
Methotrexate 7.5 mg 595 — 1188 — 1783 58.4 31 1526 2290
Methotrexate 15 mg 1190 — 1188 — 2378 71.6 33 1660 2491
PUV-A 3737 — 106 11 3854 92.9 41 2074 3111
3737 — 106 11 3854 61.1 63 3154 4731
Broadband UV-B + 3792 — 618 54 4464 80.7 55 2766 4149
acitretin 25 mg
Broadband UV-B 4600 — 106 18 4724 83.7 56 2822 4233
4807 — 106 18 4931 80.1 62 3078 4617
4558 — 106 18 4682 47.0 100 4981 7472
Narrowband UV-B 4558 — 106 18 4682 73.0 64 3207 4811
PUV-A + acitretin 20 mg 6773 — 618 49 7440 97.3 76 3823 5735
Cyclosporine 3 mg/kg 5019 — 1794 138 6951 52.0 134 6683 10,025
Cyclosporine 1.5 mg/kg 2789 — 1794 138 4721 33.4 141 7067 10,600
Acitretin 50 mg 12,359 — 618 83 13,060 60.4 216 10,811 16,217
Infliximab 5 mg/kg 24,898 1422 116 — 26,436 82.8 319 15,964 23,946
Etanercept 50 mg 21,052 0 106 — 21,158 64.2 330 16,478 24,717
Efalizumab 1 mg/kg 17,836 0 163 — 17,999 52.0 346 17,307 25,960
Alefacept 15 mg IM 23,880 806 2412 — 27,098 45.0 602 30,109 45,163
Rx, therapy; Del, delivery; Mon, monitoring; AE, adverse events; PASI%, average percentage change in Psoriasis Area and Severity Index score from
baseline to end point; PUV-A, psoralen with UV-A.
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These findings, which were based on
expert opinion of PASI efficacy, mir-
ror ours in that methotrexate, PUV-
A, and UV-B were the least costly
treatments, followed by cyclosporine
and acitretin monotherapy; com-
bined UV treatment with acitretin
was not included in their analysis.
Rapp and colleagues53 also found
that biologic agents were the most
costly therapies, and among these,
infliximab was relatively less costly
than etanercept or alefacept.
There is no doubt that the suffer-
ing of patients with moderate to se-
vere psoriasis can be extensive. Pa-
tients may endure pain, disfigure-
ment, and decrements in quality of
life.53 Although treatment with toxic
or expensive medications may be
well justified, decisions about which
treatments to apply, and the order 
in which they are initiated, should 
take into account safety, efficacy, 
and costs.54
The most costly medications
were not necessarily the most effec-
tive. Biologic treatments do not ap-
pear to be as cost-effective as oral sys-
temic agents, phototherapy, or pho-
totherapy used in combination with
acitretin. Although biologics may
present as an important option in the
psoriasis treatment armamentarium,
our results do not justify positioning
biologics as first-line therapy for
moderate to severe psoriasis.          ■
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